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ABSTRACT 
Platelet aggregation is a complex process that results in side effects for patients 
with diabetes, atherosclerosis, stroke and heart attack.  Although thoroughly studied, the 
details of the aggregation cascade are not determined.  The mechanism for participation 
of protein disulfide isomerase (PDI) in platelet function has received attention in 
literature however has not been established.  In addition, heat shock protein 70 (Hsp70) 
was found on the platelet surface and was investigated for its role in platelet aggregation.  
Thymosin β4 was of interest as a potential effector in platelet aggregation.  An additional 
goal of the study was further optimization of the flow cell chamber platelet aggregation 
model. 
UV-VIS Spectrophotometric and flow cell chamber data that indicate no 
significant effect of excess platelet surface PDI, b-b’ or Hsp70 on platelet aggregation 
and adhesion.  However, Thymosin β4 has been shown to positively affect rates of platelet 
aggregation at the doses of 1-10 μg/mL. 
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Chapter 1  GENERAL INTRODUCTION 
1.1 Platelets 
1.1.1 Introduction 
Platelets are small anucleate cellular structures that exist in the blood and are 
involved in the processes of hemostasis, wound healing and atherosclerosis.  They are 
produced by mature megakaryocytes that are generated by the proliferation and 
differentiation of hematopoietic stem cells through megakaryocytic progenitors (3).  
Platelets carry out their primary function in hemostasis and wound repair, controlling 
bleeding upon vascular injury through a complex series of events.  In short, platelets are 
able to sense the vessel wall injury, adhere to the site of injury, undergo morphological 
changes that attract other platelets to the site of the injury and begin formation of a tough 
plug that halts bleeding and begins the first stages of healing.  Many bleeding disorders 
are caused by platelet dysfunction, such as Thrombocytopenia and VonWillebrands 
disease, and result in increased bleeding times or absence of clotting in patients.  These 
disorders are very difficult to treat and if handled carelessly can result in injury and death.   
 
1.1.2 Platelet Formation 
Platelets are formed by Megakaryocytes, myeloid cells that reside in the bone marrow 
but can be found in the yolk sack and fetal liver prior to the time when marrow cavities 
have formed in the bone.  Megakaryocytes develop from pluripotent human stem cells.  
The process of platelet formation, outlined in figure 1-1, begins with Megakaryocytes 
enlarging in a process known as endomitosis; which is promoted by the signaling 
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molecule thrombopoietin.  In endomitosis DNA is replicated up to 64 fold per cycle, and 
the nuclear envelope begins to break down.  However, normal cell replication fails to 
proceed, and is halted at anaphase B, therefore bypassing telophase and cytokinesis.  
After the nuclear envelope reforms, there is a range of 4N up to 128 N per 
megakaryocyte (4).  At the same time, the demarcation membrane system (DMS) 
matures, constituting a tubule network that associates with the plasma membrane and is 
thought to act as a reservoir for proplatelet production (5). 
The open canalicular system, an open channel system designed for α-granule 
shuttling, is also formed during the cell expansion phase, prior to proplatelet production.  
The packaging of α-granules begins at this stage of cell expansion, with VonWillebrand 
Factor (VWF), receptors and other important platelet associated proteins shuttled into the 
secretory granules from the megakaryocyte.  Other important platelet proteins such as 
fibrinogen are collected from the extracellular space via endocytosis/pinocytosis and also 
packaged into α-granules.  Platelet biogenesis begins with the creation of proplatelets, or 
long pseudopodia-like extensions of the megakaryocyte cytoplasm driven by the thick 
linear bundles of microtubules in the proplatelet shaft.  The polymerization and 
elongation of the microtubules appears to be dynein-facilitated, with the tubules growing 
both toward the body and towards the free end at which point the tubule rounds and re-
enters the shaft, giving the bulbous appearance at the free end.  One platelet will develop 
from each of these long proplatelet extensions; however, extensive end amplification 
allows bifurcation of proplatelet extensions; figure 1-1 depicts the process of platelet 
biogenesis and the extensive end amplification that can occur.  Organelles and α-granules 
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are shuttled to the proplatelet tip along the microtubules.  Over time the pseudopodial 
extensions taper, and the platelet pinches off from the megakaryocyte (2). 
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Figure 1-1 Megakaryocyte platelet biogenesis (2) 
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1.1.3 Platelet Activation 
Platelets are activated by many different agonists, and are capable of responding to 
these agonists in a relatively redundant way.  The list of physiologically relevant agonists 
includes thrombin, adeniosine diphosphate (ADP), epinephrine, calcium ionophores (A 
23187), fibrinogen, collagen and thromboxane A2 (TXA2) (6).  Upon activation by an 
agonist, platelets undergo morphological changes mediated by cytoskeletal components, 
extending filopodia from the cell and releasing dense and α-granules into the extracellular 
space.  Secreted compounds serve to further activate the platelet from which they were 
released, to attract and activate passing platelets, to initiate wound repair and to play a 
role in inflammation (7).  As platelets become activated, they adhere to the site of vessel 
injury via cell surface integrins and receptors, become sticky and irregularly shaped and 
spread across the area of attachment.  The contents of the secreted α-granules activate 
nearby platelets, causing them to become sticky and adhere to one another as well as 
those that have bound to the site of injury, forming a clot.  The release of fibrinogen and 
thrombin allows the production of fibrin monomers, which cross-link to form a mesh that 
strengthens and reinforces the clot, preventing further blood loss.  The multitude of 
signals capable of activating platelets establishes a failsafe mechanism, to ensure blood 
loss is minimal even if one or more signaling systems are impaired.   
 
1.1.4 Thrombin Activation 
Thrombin is a 36 kDa serine protease that is produced from a zymogen conversion of 
prothrombin in the coagulation cascade of activated platelets.  Thrombin converts 
fibrinogen to fibrin monomers, as mentioned before, but also elicits shape change in 
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platelets, release of platelet activators via α-granules and mobilization of P-selectin to the 
cell surface (8).  Thrombin also exerts effects on other cells, including eliciting cytokine 
production in the endothelium and acting as chemo-attractive factors for monocytes and 
lymphocytes (8).  Active thrombin exerts its effects upon cells by communicating with 
the human protease activated receptor-1 (PAR-1), cleaving it between Arg41 and Ser42 
at the N-terminus thereby exposing a new amino terminus (9).  This new N-terminus acts 
as a tethered ligand, activating itself and allowing coupling with G-protein coupled 
receptors (GPCR) such as G12/13, Gq and Gi (8), activating a milieu of intracellular 
signaling cascades such as those shown in Figure 1-2.   
 
1.1.5 Integrin Activation 
Integrin molecules are adhesion receptors that reside in the plasma membrane of 
platelets and other cells, to function as cell adhesion molecules and receptors.  They exist 
as glycosylated heterodimers composed of transmembrane α and β subunits that are non-
covalently associated; each subunit possesses a large extracellular domain, a single 
transmembrane domain and a small cytoplasmic domain. (10) 
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Figure 1-2: Downstream targets and effectors following proteolysis of PAR-1 by 
thrombin in platelet aggregation. 
  
Chapter 1: General Introduction 
8 
 
 
 
Figure 1-3. Integrin α 2b β3 extracellular domain structure and affinity states 
(10).  When in the bent conformation the integrin assumes a low affinity state; as it 
moves from the extended closed conformation to the extended open conformation, 
the affinity increases achieving the extended open conformation once bound to 
fibrinogen.  In inside-out signaling, interactions between the lower legs are 
disrupted, initiating the switchblade unfolding of the integrin. 
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Integrins usually exist in a low-affinity binding state until activated via intracellular 
signals; this is termed ‘inside-out’ activation, a key step in integrin activation during 
platelet aggregation.  As shown in figure 1-3, integrins assume many different 
conformations dependent upon the affinity state, moving through a bent conformation 
into an extended conformation with a closed headpiece, then to an extended conformation 
with an open head piece when going from lowest to highest affinity states respectively 
(11).  The α2B β3 integrin is platelet specific, and assumes the extended open 
conformation once bound to fibrinogen; the binding site for fibrinogen is a pocket loop 
that forms on the integrin head piece between the α2B β-propeller and the β3-I domain 
specificity determining loop (SDL) (12).  Inside-out signaling is initiated by activators 
(such as Talin-H) binding on the cytoplasmic face of the integrin, disrupting the 
hydrophobic and electrostatic interactions between the membrane proximal helices of the 
α2B and β3 cytoplasmic tails (13).  Disruption of the binding between the membrane 
proximal helices triggers events that transmit the signal through the transmembrane 
segments to the extracellular domain.  The exact mechanism of this signal transfer in the 
transmembrane domain is controversial; however it appears to cause disruption of the 
interactions in the extracellular domain between the lower α and β legs, further 
destabilizing the bent conformer’s headpiece-tailpiece interaction, resulting in a 
switchblade-like opening of the integrin into the extended conformation.  Recent 
evidence also suggests that extracellular domain conformational changes resulting in a 
high affinity state are dependent upon disulfide bonding pattern changes between the 
many cysteine residues in the extracellular subunits (14-15).  It has been shown that the 
exposure of free thiols is necessary for integrin binding, therefore thiol-dependent 
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ligation in α2B β3 integrin may be required for integrin adhesion to fibrinogen (16).  This 
points towards a possible role for protein disulfide isomerase (PDI) in platelet activation 
on the cell surface, though there remains controversy about whether integrins retain their 
own isomerase activity or whether an external isomerase is required. 
1.1.6 Heat Shock Protein 70 on the Platelet Surface 
Heat Shock Protein 70 (Hsp70) is a well known intracellular protein that is 
responsible for molecular chaperone function: a director of proper protein folding and 
unfolding, acting as a sensor for lethally mis-folded and aggregated proteins that can lead 
to cell death, or apoptosis.  However there is recent evidence that Hsp70 is secreted from 
cells through three possible pathways and can have extracellular functions related to 
immunity and inflammation.  These possible pathways include: secretion from an 
endolysosome; leakage from necrotic or apoptotic cells; or packaging and release in 
vesicles that bleb from the plasma membrane then lyse to release their contents (17-18). 
After finding Hsp70 in supernatant of a platelet surface ethanol wash, a 
hypothesis that Hsp70 has a role in platelet aggregation on the external surface of the cell 
was developed (unpublished data).  In the literature, Hsp70 has been investigated for its 
roles in the vasculature, with speculation that elevated levels of Hsp70 may protect 
against cardiovascular disease (19-20).  As well, Hsp 70 levels in type I diabetic patients 
have been found to be inversely associated with macro and micro-vascular complications 
(21).  In pediatric Immune Thrombocytopenic Purpura patients—an autoimmune disease 
that destroys platelets-- increased levels of plasma antibodies against Hsp70 have been 
discovered (22), and there has been some speculation that heat shock proteins alongside 
protein phosphatases have a role in platelet aggregation (23).  All of this research points 
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to a role for Hsp70 in hemostasis and thrombosis, however, what that role is has yet to be 
determined.   
 
1.2 Protein Disulfide Isomerase 
 
1.2.1 Introduction 
Protein disulfide Isomerase (PDI) is a ubiquitous 58 kDa thiol-disulfide 
oxidoreductase protein found in the endoplasmic reticulum (ER) of eukaryotic cells.  It is 
a member of the thioredoxin superfamily of proteins, and is capable of disulfide exchange 
(24).  In the ER, PDI is responsible for disulfide bond breakage, formation and 
rearrangement necessary for proper protein folding (25).  Disulfide bonds are important 
for stability of protein structure and as redox responsive regulatory switches, all 
contributing to cell viability.  Although PDI is largely considered to be an ER-localized 
protein due to its c-terminal KDEL retention signal (26) it has been found in other locales 
including the surface of human platelets (27), as a non-catalytic sub-unit of prolyl 4-
hydroxylase (28) and as a subunit of the microsomal triglyceride transfer protein (29); 
however, PDI’s full contribution in all of these respects has not yet been completely 
defined. 
 
1.2.2 Domain Structure and Catalytic Activity 
PDI is a five domain protein with overall domain structure of a-b-b’-a’-c.  Each of 
the a, a’ and b, b’ domains all adopt the secondary structure of the thioredoxin fold, with 
the sequence βαβαβαββα (30).  The crystal structures of the a and b domains are shown 
Chapter 1: General Introduction 
12 
 
in figure 1-4, with the thioredoxin fold shown in blue.  Within the N-terminus of the 
second α-helix of the a and a’ domains are the active site motif sequences— Cys-Gly-
His-Cys—which are analogous to the thioredoxin motif sequence of –C-X-X-C – and 
constitute the independent active sites capable of thiol oxidation, reduction and 
Isomerization (31-32).  The crystal structure of PDI has been researched most recently by 
Nguyen et al. in 2008 who have discovered that the molecule forms a ‘boat’ shaped 
arrangement, rather than the ‘twisted-U’ originally reported by Tian et al in 2006, such 
that the two a domains do not necessarily face each other across the catalytic cleft as was 
previously thought; the b and b’ domains form a rigid platform from which the a and a’ 
project, with the a domain being the more flexible of the two (33-34).  As a result PDI 
appears to possess a more adaptive and flexible catalytic pocket than was originally 
thought, which is able to bind substrates of many different sizes and conformations (33, 
35).  The b and b’ domains have been characterized as protein binding domains due to 
the hydrophobic residues within these domains lining the inside of the catalytic pocket, 
and are therefore thought to be responsible for proper protein positioning next to the 
catalytic domains as they are themselves catalytically inactive (36).  The catalytic activity 
of PDI as shown in Figure 1-4, is capable of forming, breaking or isomerizing mis-paired 
disulfide bonds using redox reaction chemistry: one chemical species attains a higher 
oxidation state through the gain of electrons, while the other species is reduced and loses 
electrons. 
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Figure 1-4 The a and b domains of human PDI.  The a domain contains five-
stranded mixed b-sheets surrounded by four a-helices.  The active site motif lies 
between C36 and C39 at the N-terminus of a2. There is virtually no sequence 
similarity between the domains (32) 
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Figure 1-5 The redox-dependent activities of PDI.  By forming mixed disulfides 
with cysteine residues, PDI is able to form and break disulfide bonds producing a 
protein with free thiols, disulfide bonds or shuffled disulfide bonds 
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Free thiol groups on unpaired cysteines can be oxidized by PDI to form a disulfide bond 
between two sulfur atoms, both of which attain a -1 oxidation state as the protons are 
transferred to the PDI active site thereby reducing it to a dithiol state (37).  An interesting 
and recently discovered property of PDI is that it can exist as a dimer in solution and in 
the ER, with 9.7% of the monomer surface being buried; of this buried portion, 17% of 
the contact interface is contributed by the a domain, with the remaining domains 
contributing the balance equally (34).  This further suggests the increased flexibility of 
the a domain, possibly making it the primary mediator of the enzyme’s interaction with 
proteins of many differing sizes and conformations. 
The b domain appears to possess molecular chaperone properties as it is able to 
bind small peptides, allowing PDI to recognize and interact with proteins and co-
operating with the a and a’ domains for larger protein interactions.  These molecular 
chaperone domains allow for positioning of substrates in the active site in such a way to 
expose buried thiols or disulfide bonds, to prevent improper interactions between 
partially folded intermediates, for targeting the thiols or disulfide bonds that specifically 
need attention and for recognition of improperly folded proteins in more than one 
intermediate state (32).  The binding of proteins to PDI at one site appears to happen with 
fairly low affinity; however, the binding is multiplicative with each additional binding 
site contributing to an increase in binding affinity.  It is thought that as the proper protein 
folding and structure is established by forming proper native bonds, the protein will bind 
to fewer and fewer sites on PDI, eventually having the lowest binding affinity when 
proper native conformation is achieved.  The acidic C-domain posesses the KDEL-ER 
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retention sequence, and does not appear to contribute to the enzymatic function of the 
protein (38). 
The redox state of PDI’s active site is largely dependent on the ratio of reduced to 
oxidized glutathione ([GSH]/[GSSG]) in the compartment in which it resides (39); in the 
ER this ratio is approximately 3:1, creating a reducing environment.  The oxidation of 
PDI in the ER is thought to be due in large part to Ero1, an oxidative exchanger which 
recharges PDI by reducing flavin adenine dinucleotide (FAD) to FADH2, using molecular 
oxygen as a terminal election acceptor, thereby producing H2O as a by-product (40).  In 
vitro, PDI’s active site thiols can also be reduced or oxidized by GSH or GSSG, 
dithioltrietol (DTT) and reactive oxygen species (41). 
 
1.2.3 PDI in Platelet Aggregation 
Potential targets for PDI on the platelet cell surface include the collagen receptor and 
surface integrin α2β1 (16), and the fibrinogen receptor and integrin α2bβ3 (15).  These all 
appear to require disulfide bond exchange or re-arrangement to induce an active state 
conformation which initializes signalling pathways that subsequently activate platelet 
aggregation (42).  A proposed disulfide bond re-shuffling mechanism shown in Figure 1-
6 outlines how PDI might interact with the extracellular integrin disulfide bonds to 
initiate an active state conformation.  The α2β1 collagen receptor has been shown to form 
intra-receptor stabilizing disulfide bridges during its high affinity state (43), which 
suggests a role for a disulfide isomerase in switching the integrin to its active 
conformation.  This was corroborated by evidence that platelet adhesion to collagen was 
inhibited by the anti-PDI antibody RL-90 (16). 
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Yan et al have shown that in the α2bβ3 integrin, multiple unpaired cysteine 
residues exist in the β3 subunit which are postulated to comprise a key modulatory redox 
site for integrin activation.  The importance of the cysteine-rich domain in the integrin β3 
subunit and the possible role for PDI regulatory acitvity at this site are supported by the 
following discoveries.  The conformational changes that coincide with integrin activation 
have been mapped to the disulfide rich region of the β3 subunit (44).  Cysteine 
substitutions in the EGF-like domains of the β3 subunit were found to cause decreased 
surface expression of the integrin when double or single mutations in the EGF-like 3rd 
and 4
th
 domains were applied; additionally several different cysteine mutations in the 
EGF-3-like domain caused consitutive activity of the receptor, while disruption of the 
cys567-cys581 disulfide bond in the EGF-4-like domain caused a completely inactive 
state (45).  DTT has been shown to initiate a slow acting platelet aggregation through 
reduction of disulfide bonds (46).  Finally PDI inhibitors have been shown to attenuate 
α2bβ3 activation on the surface of the platelet (47). 
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Figure 1-6  A model of the proposed disulfide bond shuffle that occurs in 
integrins on the platelet surface.  Resting and active integrins differ in the number 
and positioning of unpaired cysteines (44). 
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1.2.4 PDI in Other Roles 
Although PDI clearly has many roles as an independent protein, it can also function 
as a subunit of other larger enzymes .  The enzyme human prolyl 4-hydroxylase acts upon 
collagen and other proteins forming 4-hydroxyprolines by hydroxylating proline residues, 
which are necessary for stabilizing the collagen triple helix (28).  The enzyme is an α2β2 
tetramer, where PDI serves as the β-subunit and one of its roles is to retain prolyl 4-
hydroxylase in the ER via the C-terminal KDEL retention signal.  PDI also acts as a 
chaperone for prolyl 4-hydroxylase by keeping the α-subunits in a nonaggregated and 
catalytically active form; this activity is unable to be mimicked by any substitute non-PDI 
chaperone proteins such as Hsp70 (48).  The same molecular chaperone activity that PDI 
contributes to prolyl 4-hydroxylase appears to also occur when it is a subunit of the 
enzyme microsomal triglyceride transfer protein.  The microsomal triglyceride transfer 
protein is a soluble ER αβ dimer protein that is required for the assembly and secretion of 
very-low-density lipoprotein from hepatic cells and chylomicrons from enterocytes.  PDI 
is the β-subunit in this protein as well, where again its role appears to include ER 
retention of the αβ dimer and maintaining the solubility and catalytic activity of the α-
subunits, but not appearing to contribute to the enzymatic activity of the dimer with its 
usual isomerase activity (49).   
PDI is also capable of denitrosating S-nitrosoglutathione and other S-nitrosylated 
compounds (RSNO) resulting in the release of nitric oxide (NO), as reported by Sliskovik 
et al in 2005.  NO is a ubiquitous signalling molecule which is especially significant in 
the cardiovascular system, where release of NO into the vasculature induces 
vasorelaxation and inhibits platelet function.  It has been suggested that there exists a role 
for PDI in catalyzing transmembrane tranfer of NO, first relieving it from an RSNO 
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source (50).  Studies on the mechanism of PDI denitrosation of S-nitrosothiols suggests 
that the cysteines in the CXXC motif of the active sites attack the RSNO substrate, 
undergoing a transnitrosation reaction and forming a nitrosyl disulfide intermediate, 
which ultimately results in release of NO leaving the PDI active site oxidized.  
Furthermore when NO levels are high, PDI is capable of accumulating NO within its 
hydrophobic domains, storing it as N2O3 (a potent nitrosating agent), thus nitrosating the 
nearest vicinal thiols within PDI and forming PDI-SNO.  In this manner PDI can act as a 
sink for NO, carrying it across the membrane where cell surface PDI denitrosates it, 
releasing it into the extracellular environment. 
1.3 Flow Cell Methodology Development 
 
1.3.1 Introduction 
As previously noted, the role of platelets in hemostasis and thrombosis begins with 
adhesion to the site of vascular injury.  The current methods for assessment and 
investigation into platelet adhesion to various matrices under various conditions are not 
sufficiently reliable, are expensive and are often not physiologically relevant.  Popular 
methods include passing of blood over coverslips coated with proteins such as fibrinogen 
(51), aggregometry in spectophotometers and plate readers; the bleeding time test; 
impedence aggregometry in whole blood (52); Platelet Function Analyzers which 
measure occlusions of apparati as an indication of wound closing time (53); flow 
cytometry as a measure of platelet activation and sensititivty to agonists using 
fluorescently conjugated monoclonal antibodies (54); and measurement of secreted α-
granules and their contents in response to agonists.  Our group has sought to create a 
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reliable, inexpensive and accessable method for investigating platelet adhesion and 
aggregation in a physiologically relevant setting using teflon boundary flow chambers, 
constructed internally with a polydimethylsiloxane (PDMS) surface coated with proteins 
of interest.   
 
1.3.2 Surface Chemistry 
The PDMS surface was manipulated chemically to ensure that any proteins applied 
there would be tethered to the surface, rather than merely associated with it.  The 
otherwise inert PDMS, when subjected to plasma oxidation, possesses exposed hydroxyl 
groups on the surface.  These hydroxyl groups provide the ideal place for linker 
compounds, such as the one used in this study 5% aminopropyltrimethoxysilane 
(APTMES), to react.  The exposed amines of APTMES furthermore provide an excellent 
target for subsequent linker compounds such as the one used in this study, the amine 
reactive bis(sulfosuccinimidyl) suberate (BS3), and other linkers such as disuccinyl 
suberate (DSS).  The final compound BS3 provides the last link between the 
aformentioned covalent linkers and the protein of interest, which in this study was 
fibrinogen, but could be a variety of proteins including collagen.  The final chemical 
scheme of the immobilization of fibrinogen onto plasma oxidized PDMS is shown in 
Figure 1-7. 
This method allows investigators to pass whole blood over the PDMS surface under a 
microscope, and quantify platelet adhesion to the proteins of interest, with the ability to 
add and manipulate many variables including, but not exclusively, compounds, sheer 
stress rates, temperature and light.    
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Figure 1-7  The surface chemistry of PDMS flow cells for immobilization of 
proteins.  Plasma oxidation exposes hydroxyl groups on the PDMS surface that are 
bound by APTMES, APTMES subsequently links to BS3 which in turn binds 
fibrinogen. 
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1.4 Thymosin Beta Four 
 
1.4.1 Introduction 
The β-thymosins are small, acidic 5 kDa peptides that are ubiquitous and highly 
conserved among species.  They were originally thought to be thymic hormones, but have 
since been identified as G-actin sequestering peptides participating in cell movement and 
cytokinesis (55-56).  Thymosin β4 (Tβ4) is present in concentrations from 0.1 μM up to 
560 mM in a variety of tissues and cell types, including platelets, where its main role is to 
bind free actin, or G-actin, thereby inhibiting association with the F-actin filament (57-
58).  Specifically in platelets Tβ4 has been shown in high concentrations, with levels of 
free Tβ4 increasing after activation with thrombin corresponding to the polymerization of 
F-actin and a decrease in the levels of the Tβ4-actin complex, allowing platelets to 
change shape and to elicit their physiological response in blood clot formation (59).  Tβ4 
is also co-released with factor XIIIa (plasma transglutaminase) from platelets following 
activation with thrombin and is integrated locally into fibrinogen monomers and fibrin 
polymers within the hemostatic plug at their αC-domains (60-61).  Decreased levels of 
Tβ4 in cancer cell lines has been noted by various groups, and has led to postulated roles 
for Tβ4 in the cell cycle and immunity (62).  Sosne et al studied the effect of Tβ4 
administration on corneal epithelial wounds and found that Tβ4 is also involved in wound 
healing and cell migration, as well as possessing anti-inflammatory and anti-apoptotic 
properties (63). 
 
1.4.2 Domain Structure and Activity 
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Thymosin β4 is a peptide that is largely unstructured in water, but has a tendency to 
form α-helical structures in aqueous solutions containing fluorinated alcohols (64).  
Circular dichroism analysis has suggested that isolated Tβ4 has an average of six helical 
residues and its actin-bound form contains up to 12 helical residues (65).  Thymosin β4 
binds to actin with an equilibrium dissociation constant of KT= 1 to 2 μM (66).  Various 
molecules such as profilin and DNase 1 have shown competition with Tβ4 for binding 
free actin, some due to steric overlap, with DNase 1 able to form a ternary complex with 
Tβ4-actin (67).  Recently Yarmola et al have shed greater light on this competitive 
binding scheme and determined that at concentrations higher than 5-10 μM the prevailing 
event is non-competitive inhibition, due to the existence of ternary complexes and 
allosteric changes in actin; however there have also been reports that intra-platelet 
concentrations of Tβ4 range from 200-500 μM (57).  In order to bind G-actin, the N-
terminus of Tβ4 must adopt an α-helical conformation, exposing an important 
hydrophobic residue 
6
Met.  When 
6
Met is exposed the N-terminal binding motif 
17
LKKTETQ
23
, and possibly also 6 important N-terminal amino acids, become properly 
positioned to participate either directly or indirectly in binding the C or N-terminus of 
actin between sub-domains 3 and 1 (67-69).  Figure 1-8 depicts the actin filament 
formation process within the cell, tread milling between monomer addition on the barbed 
end by profilin and monomer disassembly on the pointed end by Tβ4.  The balance of 
these processes depends on concentrations of the regulators.  However, Tβ4 has two 
orders of magnitude higher affinity for ATP-G-actin (free) than ADP-actin which is 
contained within the polymer.  Hence, the concentration of free actin in the cytoplasm is 
the main regulator of disassembly, and the concentration of free actin is heavily 
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dependent upon the concentration of Tβ4:  once actin is sequestered by Tβ4, the Tβ4-
actin complex no longer contributes to the free actin pool.  The equilibrium is balanced as 
follows, where [TA]ss is the Tβ4-actin complex, [A]ss is free G-actin, [T] is the 
concentration of Tβ4 and KT is the equilibrium constant (66): 
[TA]SS = [T]0.[A]SS/([A]SS+KT) 
 
The role of Tβ4 appears to be vastly different on the surface of the platelet.  There has 
been much research about the effects of Tβ4 on endothelial cell migration as a 
chemoattractive factor in wound healing; also elevated levels of Tβ4 have been 
discovered around areas of blood vessel and neuronal growth (70-71).  As a result of 
these accumulated findings, there has been speculation that upon injury Tβ4 is released 
from activated platelets and inserted into the fibrin/fibrinogen matrix that forms around 
the wound in an effort to keep the local concentration of Tβ4 relatively high.  A higher 
local concentration of Tβ4 may be needed to stimulate the epithelial cell migration and 
angiogenesis necessary to close and heal the wound.  The presence of Tβ4 has also been 
associated with anti-inflammatory properties, and as such does not appear to stimulate 
macrophage migration (58).  Although these effects of Tβ4 have been researched and 
documented, the processes by which it contributes to wound healing, angiogenesis and 
platelet aggregation are not fully elucidated. 
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Figure 1-8  Tread milling process of actin, 
with addition and dissociation of actin monomers 
happening at opposite ends of the filament.  
Thymosin would act to sequester the actin 
monomers (shown in orange); permission to use 
the image acquired from the author  (1). 
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OBJECTIVES 
1. Optimize the flow cell chamber experiment: determine the cause of fibrinogen dot 
peeling and identify the most robust and effective platelet fluorescent label 
2. Investigate the effects of excess platelet surface protein on platelet aggregation—
Protein disulfide isomerase for its potential role as a cell surface oxidoreductase, 
the b-b’ subunit of protein disulfide isomerase for its potential role as a chaperone 
for the critical disulfides in the α2bβ3 integrin, and heat shock protein 70 for its 
potential role as a platelet surface chaperone protein or ATPase. 
3. Investigation into the effect of the redox state of platelet surface protein disulfide 
isomerase and the whole blood environment on platelet aggregation 
4. Investigate the effects of Thymosin β4 on platelet aggregation 
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Chapter 2 MATERIALS AND METHODS 
2.1 Materials 
Hepes (EMD); sodium chloride (ACD Chemicals Inc); Sodium phosphate dibasic 
(ACD Cehcmicals Inc); Potassium chloride (ACD Chemicals Inc); D-glucose (sigma); 
Trisodium citrate dehydrate (EMD); citric acid monohydrate (BDH Chemicals); 8 mL 
ACD Vacutainer Whole Blood Collection Tubes  (VWR); fluorescein isothiocyanate 
(Fluka); dimethyl sulfoxide (EMD); Kanamycin (Sigma); Tryptone (Sigma); Yeast 
Extract (EMD Chemicals Inc); Potassium phosphate monobasic (ACD Chemicals Inc); 
Tris-HCl (ACD Chemicals Inc); Imidazole (Sigma); Lysozyme (Sigma); DNase 1 
(Sigma); Phenylmethanesulfonyl fluoride (Sigma); Triton x100 (Sigma); 30% 
Acrylamide (Bio-Rad); Tris-(Hydroxymethyl) Aminomethane (ACP Chemicals Inc.); 
Sodium dodecyl suflate (Sigma); Ammonium persulfate (Sigma); Temed (EMD 
Chemicals Inc.); Glycine (EMD Chemicals Inc); Methanol (U.W CCC);  Glutathione 
sepharose 4B beads (GE Healthcare); Precission Protease (GE Healthcare);  HIS-Select 
Nickel Affinity Gel (Sigma); Glutathione, oxidized (Sigma); Glutathione, reduced 
(sigma);  Eosin Isothiocyanate (Fluka); EDTA (Fischer Scientific); G25 Sepharose 
(Sigma); Potassium phosphate (ACP Chemicals Inc.);  Sylgard 184 Silicone Elastomer 
Kit (A.E Blake Sales Ltd.); 3-Aminopropyl-trimethoxysilane (Aldrich); BS3 (Thermo 
Scientific); Fibrinogen (Sigma); CaCl2 (ACD Chemicals Inc); Plasma Cleaner (Harrick 
Plasma PDC-32G); pump (Reglo Digital MS 4/6, model ISM 833, Ismatec); PTFE Teflon 
sterile tubing (0.031” X 0.062”); Microscope (Zeiss); Retiga EX, cooled Mono 12 bit 
Camera (Q Imaging); Northern Eclipse Software (Empix Imaging Inc); Cuvette 
(Sarstedt); Spectrophotometer (Agilent); Thrombin (Sigma); BODIPY® FL N-(2-
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aminoethyl)maleimide (Invitrogen); 5,5’-Dithiobis(2-nitrobenzoic acid) (Sigma); sodium 
acetate (Sigma) 
 
 
2.2 Methods 
 
2.2.1 Blood Acquisition 
Blood was obtained from the arm veins of healthy volunteers and collected in blood 
collection tubes containing ACD.  The tubes were stored upright at room temperature 
until the contents were used. 
 
2.2.2 Platelet Isolation and Preparation 
Whole blood was centrifuged at 400 RPM for 30 min at room temperature and 
platelet rich plasma (PRP) supernatant was decanted.  0.5 μM Prostaglandin E1 was 
added to PRP prior to centrifugation at 600 RPM for 15 min (72).  Plasma supernatant 
was removed and stored at room temperature for later use in flow chamber experiments.  
The platelet pellet was carefully removed from the surface blood pellet, re-suspended in 
Hepes-ACD buffer and subsequently centrifuged at 600 RPM and re-suspended until the 
blood pellet was removed.  Isolated platelets were stored resuspended in Hepes-ACD at 
room temperature on a nutator and used the same day.  If the platelets were to be used in 
a flow chamber experiment they were labeled with fluorescein isothiocyanate (FITC) at a 
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concentration of 48 μg/ml for 10 minutes at room temperature, washed twice with re-
suspension in Hepes-ACD  and used immediately(73).  The same procedure was used for 
platelets labeled with Bodipy®FL N-(2-aminoethyl)maleimide (Bodipy-FL) at a final 
concentration of 0.5 μM (74) and Cell Tracker Green 5-chloromethylfluorescein 
(CMFDA) at a final concentration of 2.5 μM (75).   
 
2.2.3 Cloning of Hsp70 
Cloning was performed by Tanya Marar under the supervision of Dr. Bulent Mutus 
and Dr. Sirinart Ananvoranich.  The human hsp70 gene was cloned from the pEGFP 
hsp70 plasmid into the pET21a+ vector using EcoRI and HindIII restriction enzymes.  A 
1932 bp insert was generated with a C-terminal His6tag.  The vector was transformed into 
BL21 (DE3)  pLysS E. coli. 
 
2.2.4 Protein Purification 
PDI, Hsp70 and the B-B’ domain of PDI were all purified from BL21 (DE3) E. coli.  
Glycerol stocks were thawed at room temperature and used to inoculate 50 ml of 
autoclaved terrific broth (TB) containing kanamycin at a concentration of 25 μg/mL.  
After growing overnight, 1 ml of the culture was used to inoculate an identical 1 L of TB.  
Following 3 hours of growth the OD540 was assessed and the culture was allowed to grow 
until it reached an OD of 0.4 to 0.6 was reached.  The culture was then induced with 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and centrifuged at 6000 RPM for 30 
min at 4° C.  Cells were re-suspended in lysis buffer and incubated on ice for 20 min 
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followed by sonication.  The lysate was centrifuged at 12,000 RPM for 30 min at 4°C.  
The supernatant was run over a nickel affinity column in the case of both PDI and Hsp70 
due to their His6 tags, to isolate the protein of interest.  The B-B’ protein was isolated by 
running the lysate over Glutathione Sepharose 4B beads pre-washed in water and 
equilibrated in PBS+DTT.  Precission Protease was added and incubated overnight with 
gentle agitation.  The eluate in all cases was collected in several fractions and analyzed 
by SDS-PAGE, Western blotting (except TB4) and Bradford Assay.   
2.2.5 Protein Disulfide Isomerase Preparation: oxidation, reduction and 
isomerization 
To induce oxidation purified PDI was incubated overnight with oxidized glutathione 
(GSSG) at a final concentration of 0.01 M.  The same was done to induce the reduced 
state of PDI, using reduced glutathione (GSH) at the same concentration.  To produce 
PDI in the isomerization form a ratio of 4:1 GSSG:GSH was used with a total final 
concentration of 0.01 M.  In all cases the PDI was incubated overnight at 4°C and then 
run over a G25 column to remove GSH/GSSG.  PDI activity was assessed using the Di-
Eosin-GSSG assay(DiE-GSSG) (39) and the level of activity was used as an indication of 
the level of oxidation of the PDI active site.  For verification of deposition on the platelet 
surface, redox induced PDI was labeled with eosin 5-isothiocyanate (EITC) and 
fluorescein isothiocyanate (FITC) by incubation of PDI at minimum concentration of 2 
mg/mL with 1 mg/mL EITC or FITC.  Carbonate buffer at a concentration of 0.5 M and 
pH 8.0 was used as the main solvent, and DMSO was used to initially dissolve the EITC 
and FITC.  After incubation overnight at 4°C, PDI was run over G-25 sephadex column 
and fractions were collected and subjected to Bradford Assay and fluorescence scans to 
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verify protein concentration and fluorophore viability.  Redox induced PDI was incubated 
with isolated platelets overnight at room temperature under gentle agitation.  The 
platelets were washed twice with Hepes-ACD before being used for experimental 
purposes.   
2.2.6 Spectrophotometer Turbidity Assay Experimental Procedure 
Isolated unlabeled platelets, either treated or untreated, were added to Hepes-ACD in 
an acrylic 500 μL cuvette at a final concentration of 2x107 cells/mL.  The cuvette was 
placed inside the Spectrophotometer, and absorbance was read in kinetics mode every 2 
seconds at a wavelength of 595 nm.  After the first 30 seconds, the activator Thrombin 
was added (final concentration 1 unit/ml) with a curved glass instrument termed a 
‘plumper’ to enable quick, efficient addition combined with mixing.  The total final 
volume of Hepes-ACD + platelets + thrombin was 500 μL.  Two control treatments were 
utilized: one wherein Hepes-ACD was added in the place of thrombin and one wherein 
untreated platelets were used and activated by thrombin.  The aggregation was allowed to 
run to completion.   
 
2.2.7 Flow Chamber Assembly 
Sylgard 184 Silicone elastomer base was combined with silicone elastomer curing 
agent in a 10:1 ratio respectively, to create PDMS.  A glass cover slip formed the bottom 
of the chamber and was adhered to the square acrylic mold of the chamber with PDMS.  
After polymerization at 70°C for at least 25 minutes, the inside of the chamber was filled 
with more PDMS, using an acrylic and polytetrafluoroethylene (PTFE) tubing insert to 
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create a negative entrance space for blood to pass into and out of the chamber.  This was 
also allowed to cure at 70°C for at least one hour.  The acrylic insert was removed 
revealing the negative space, and the final coating of PDMS was applied to the remaining 
area of coverslip that was exposed, to create an entirely PDMS-lined chamber.  The flow 
cells were then subjected to plasma oxidation cleaning which allowed the normally inert 
silicone surface to contain exposed hydroxyl groups.  A solution of 5% APTMES in 
ethanol was applied in a small( <1µL) dot to the surface of the PDMS and allowed to 
bind for 15 minutes.  Following binding, BS3 (final concentration 0.125 mM) was added 
on top of the APTMES dot followed immediately by type 1 fibrinogen in 0.88% saline 
(final concentration 0.005 mM) on top of the BS3.  The chambers were incubated at room 
temperature for at least 10 minutes before being used in the flow experiments.   
 
2.2.8 Flow Chamber Experimental Procedure 
Prior to use, the flow chambers were blocked with a 1 M pH 8 Tris solution for 
approximately 2 minutes.  The flow cells were attached to an Ismatech pump as shown in 
the experimental set up in Figure 2-1.  Red Blood Cells (RBCs) and plasma were 
recombined in a 1:1 ratio, and isolated, labeled platelets were added at a final 
concentration of 2.5 x 10
7
 platelets/mL.  The pump was run at a speed of 2.00 mL/min, 
and the entire experiment was run for 390 seconds.  Images were taken every 10 seconds 
throughout the run with a Zeiss Microscope and Retiga EX, cooled Mono 12 bit camera 
using Northern Eclipse software.  After the 8
th
 image was taken, the platelet activator 
CaCl2 was added at a final concentration of 4.6 mM.    
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Figure 2-1 Experimental set up for platelet aggregations under flow.  The 
direction of blood flow is indicated by the arrows, and flows from the blood 
reservoir, to the flow cell chamber under the microscope, back to the pump and 
returning to the reservoir. 
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Chapter 2: Materials and Methods 
35 
 
2.2.9 Thymosin β4 Fibrinogen Binding Assay 
All necessary wells of a 96-well plate were filled with 50 µL of PDMS at a ratio of 
10:1, base:curing agent.  The plate was treated exactly as a flow cell, first exposing it to 
plasma oxidation then applying all necessary chemicals with an identical time course: 2 
µL of 5% APTMES in ethanol followed by 2 µL of both 2 mg/mL BS3 and 2mg/mL type 
1 fibrinogen in 0.88% saline.  Tβ4 was labeled with eosin-isothiocyanate (EITC) at a 
concentration of 10 mM in the presence of 1 M bicarbonate solution pH 8.0, at room 
temperature in the dark for 2 hours under gentle agitation.  The labeled Tβ4 was run over 
G25 column in the dark to remove unbound EITC, and subjected to Bradford Assay to 
determine protein concentration.  Before application of the labeled Tβ4, the wells were 
blocked with 1 M Tris-base; after 2 min the Tris was aspirated from the wells, and the 
various concentrations of Tβ4 were added to the wells: 0.01 µg/mL, 0.1 µg/mL, 0.5 
µg/mL, 1.0 µg/mL, 5.0 µg/mL, 10.0 µg/mL, 30.0 µg/mL, 50.0 µg/mL, 100.0 µg/mL.  
The plate was incubated under gentle agitation for 2 hours in the dark before the wells 
were washed 3 times with PBS (pH 7.0) in the dark.  The plate was read in a PerkinElmer 
Victor Multilabel Plate Reader using Workout 2.0 software. 
2.2.10 5,5’-Dithiobis(2-nitrobenzoic acid) Assay 
Plasma was isolated from whole blood by centrifugation at 400 RPM both before 
and after the flow cell chamber experiment.  A 5,5’-Dithiobis(2-nitrobenzoic acid) 
(DTNB) solution was made using 50 mM sodium acetate (NaAc), 2 mM DTNB in water.  
A DTNB working reagent was made using 50 μL of the DTNB solution, 100 μL 1 M Tris 
solution pH 8.0, and water 840 μL.  The DTNB working reagent was combined with the 
Chapter 2: Materials and Methods 
36 
 
sample at a ratio of 10:1 DTNB to plasma sample.  The solution was mixed well, then 
absorbance was read in the spectrophotometer at 412 nm.   
2.2.11 Data Analysis 
Spectrophotometric data was analyzed by determining the initial rate of 
aggregation as the slope of the line of the initial aggregation curve, between more than 4 
points.  Data from aggregations under flow were analyzed using the Northern Eclipse 
software.  A rectangular trace with area 12,375 pixels was used consistently for all 
movies taken.  The number of platelets bound and total fluorescence of the area within 
the rectangle were counted.  All data were pooled and the Y for each image (where 
Y=fluorescence value) was subtracted from the Yfinal to calculate the difference in total 
fluorescence across all images per movie.  The natural Ln of the difference produced a 
plot with the slope equaling the rate constant.  The rate constant was used to produce a 
theoretical curve using the equation: 
Y=Yfinal x (1- 1
(-1 x rate constant x time)
) 
The rate constant of the theoretical curves was adjusted until the theoretical curve fit 
the actual curve +/- 0.002.  This was done for each movie individually.  Statistical 
significance was determined using the T-test with p<0.05. 
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Chapter 3 RESULTS 
3.1 Flow Cell Methodology 
 
3.1.1 Optimizing the Surface Chemistry 
 
Initially when beginning the use of the flow cell chambers, a previous protocol was 
used that included the use of 100% APTMES on the activated PDMS surface.  Upon 
closer examination of the immobilized fibrinogen ‘dot’ following blocking with Tris, a 
peeling effect was noted.  A peeling or cracking of the immobilized fibrinogen surface is 
undesirable because it results in uneven platelet adhesion and the cracked surface can 
become loose and peel away during flow.  Both of these occurrences resulted in 
unreliable platelet adhesion measurements.  The following steps were taken to optimize 
the surface preparation to prevent the peeling effect from happening.  First, the effect of 
the 1 M Tris-blocking agent on the immobilized fibrinogen was investigated using all of 
the following as blocking agents: 1 M bovine serum albumin (BSA), 1 M glycine, 1 M 
Tris and water.  The images in figure 3-1 of the fibrinogen ‘dots’ following blocking 
demonstrate that it is not the 1 M Tris which is causing the peeling of the immobilized 
fibrinogen dots, as they all continue to peel under the different blocking conditions. 
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Figure 3-1 Variations in blocking agents do not affect fibrinogen dot peeling; the 
same extent of peeling is apparent for each type of blocking agent used, indicating 
the cause of peeling is not the process of blocking. 
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The next step undertaken to investigate the cause of the peeling effect was the surface 
chemistry responsible for tethering fibrinogen to the PDMS.  Simultaneously, both the 
length of exposure in the plasma oxidation chamber and the percent volume of APTMES 
were varied.  APTMES is soluble in ethanol, and the following percent volumes of 
APTMES in ethanol were used: 5%, 10%, 20%, and 50%.  The length of exposure times 
in the plasma cleaner were varied as follows: 0 seconds, 20 seconds, 60 seconds (Fig 3-
2); changing the length of exposure in the plasma cleaner effects the surface chemistry of 
the PDMS in the number of exposed functional groups. 
The images in Fig 3-2 display the peeling effect that occurs at APTMES 
percentages above 5%, with increasing severity as the %APTMES in ethanol increases 
(white arrows indicate sights of peeling).  Upon visual inspection it is very clear that the 
preferred percent volume of APTMES in ethanol for use as a linker to immobilize 
fibrinogen on the surface of PDMS is 5%, as this percentage did not produce the peeling 
effect at any duration of plasma cleaning.  It appeared that both the 60 second and 20 
second plasma cleaning at 5% were effective; so the length of time used in experiments 
thereafter was 60 seconds due to the distinct border it produced. The 0 second exposure 
time appeared to produce a resilient fibrinogen dot, however the web-like extensions 
around the perimeter of each dot did not produce a distinct boundary, and it is not clear 
how this web would affect platelet adhesion or dynamics within the flow cell. 
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Figure 3-2 Images of FITC-fibrinogen immobilized on the surface of PDMS 
using varying lengths of plasma oxidation and varying percent volumes of APTMES 
in ethanol.  The best combination of time in plasma oxidation and percent volume of 
APTMES in ethanol was 60 second and 5% because it produced no peeling and a 
distinct edge. 
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3.1.2 Labeling Platelets for Use in Flow Cell Experiments 
Throughout the development of this technique, more than one compound has been 
assessed for efficiency, compatibility and an absence of interference with the cellular 
processes involved in platelet aggregation.  Cell Tracker Green CMFDA dye was utilized 
to label isolated platelets, as the literature on the compound states that it does not 
adversely affect the processes involved in platelet aggregation.  CMFDA has been 
previously shown to interact with intracellular thiols following free diffusion across the 
plasma membrane and transformation by esterases into a cell-impermeant fluorescent 
thioether dye (76).  Baker et al. displayed the use of CMFDA in platelets for flow 
cytometry experiments, and claimed that the compound had no adverse effects on platelet 
aggregation processes (75); however, the opposite was observed when CMFDA was used 
in flow cell chamber experiments.  Although platelet fluorescence was robust and long 
lasting, CMFDA appeared to stunt the ability of the platelets to adhere to immobilized 
fibrinogen.  In figure 3-3 total adhesion, as a function of total fluorescence numbers, of 
platelets labeled with CMFDA was much lower than total adhesion of platelets labeled 
with Bodipy-FL . In figure 3-4 movie images taken from FITC and CMFDA labeled 
platelets shows the markedly reduced adhesion of platelets labeled with CMFDA dye. 
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Figure 3-3 A comparison of the adhesion curves for platelets in flow cell 
chamber experiments run over immobilized fibrinogen.  Platelets labeled with Cell 
Tracker Green CMFDA dye show inhibited ability to bind fibrinogen. 
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Figure 3-4 A comparison of images taken of the PDMS surface over the time 
course of a flow cell chamber experiment.  Platelets labeled with CMFDA dye show 
markedly reduced ability to adhere to immobilized fibrinogen, while platelets 
labeled with FITC do not (time measured in seconds). 
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Although Bodipy-FL was used as a standard against which to compare the 
effectiveness of the CMFDA dye, it is not without its own complications.  Bodipy-FL has 
been shown to be thiol reactive on the exofacial surface of the cell (77), which potentially 
interferes with integrin-mediated fibrinogen binding which, as previously discussed, has 
been shown to involve thiol disulfide bond shuffling.  Thus, in an attempt to use a dye 
that is not thiol reactive on the extracellular or intracellular face, amine directed FITC 
was utilized.  Unfortunately, FITC did not prove to be an effective solution for the 
platelet labeling problem.  Upon initiation of the flow cell chamber experiment 
fluorescent light is shone at the sample every 10 seconds as it flows past the light source 
and microscope field of view.  As a result, those platelets that adhere to the immobilized 
fibrinogen receive a dose of fluorescent light every 10 seconds from the time they adhere 
until the end of the run lasting a total of 390 seconds.  Photobleaching due to exposure to 
fluorescent light was observed for FITC labeled platelets over the time course of the flow 
cell chamber experiment, shown in figure 3-5, that makes accurate platelet adhesion 
measurements impossible. 
As a result of these investigations Bodipy-FL is the most effective platelet label 
for use in flow cell chamber experiments. 
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Figure 3-5  Photobleaching of platelets labeled with FITC compared to platelets 
labeled with Bodipy-FL.  Over the time-course of the flow cell chamber experiment, 
it is clear that Bodipy-FL labeled platelets are able to reflect the increase in platelet 
adhesion, while the steady decline in fluorescence seen in FITC labeled platelets 
indicates a photobleaching effect of platelets adhered to immobilized fibrinogen 
(photobleaching shown as a percent of the adhesion value at the time decay begins; 
n=4).   
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3.2 Excess platelet surface proteins 
In this study three proteins were assessed for their role and effects in platelet 
aggregation at the level of the cell surface: PDI, b-b’ subunit of PDI and Hsp70.  This 
analysis was done using a variety of techniques, one of which was turbidity assays 
performed by evaluating the extent of aggregation of platelets suspended in a cuvette as a 
measure of the decrease in turbidity within the cuvette over time.  The second technique 
used to assess the effect of excess surface proteins on platelet aggregation was the flow 
cell chamber experiment, which allows the specific targeting of the protein of interest’s 
role in the α2Bβ3 integrin mediated platelet aggregation pathway.  To deposit each protein 
in excess onto the surface of the platelet the law of mass action was utilized, and a high 
concentration of protein in solution was added to isolated platelets in suspension, tipping 
the equilibrium and causing deposition of protein on the platelet surface.  Excess surface 
protein was verified by subjecting treated platelets to a 5% isopropanol wash; SDS-
PAGE analysis of the wash supernatant (Fig 3-6) revealed more intense bands of the 
proteins of interest in treated platelets than in the native platelet isopropanol wash.   
 
Chapter 3: Results 
47 
 
 
Figure 3-6  Platelets treated with excess protein of interest were subjected to a 
5% isopropanol wash, and the wash was subjected to SDS-PAGE.  The grey squares 
indicate where the law of mass action was successful in depositing excess amounts of 
protein onto the surface of the platelet.  Using densitometery measurements in 
ImageJ the area under the curve was calculated to be (in order from left to right) 
1276, 1156, 2191, 1229, 2741 and zero. 
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3.2.1 Investigation into the role of excess PDI on the platelet surface 
There are many studies that assess the effect of PDI in platelet aggregation using 
RL90 anti-PDI antibody, the PDI inhibitor bacitracin and other competing substrates 
(47), all of which verify reliably that PDI has a role in platelet aggregation.  The question 
that still remains unanswered is, what role PDI plays and in what pathway it participates 
in the complex aggregation process.  In an attempt to further elucidate the role PDI is 
playing in platelet aggregation, excess PDI was deposited onto the surface of platelets via 
mass action to approach the investigation of PDI’s role in platelet aggregation from a 
different angle.  If PDI plays a role in a rate limiting step of the aggregation pathway, 
increasing platelet surface PDI would cause increased rates of aggregation which were 
assessed by both turbidity assays on the UV-VIS Spectrometer and platelet adhesions 
studied in the flow cell chamber experiments.  Furthermore, by applying excess surface 
PDI to platelets in the flow cell chamber experiments, the potential role of PDI in the 
α2Bβ3 integrin mediated aggregation pathway will become clearer.  PDI was deposited on 
to the surface of the platelet via mass action, and the presence of PDI on the surface was 
verified by imaging of labeled PDI on the surface (Fig 3-7).  The effective labeling of 
PDI was verified by a fluorescence wavelength scan shown in figure 3-8, showing a peak 
at 540 nm with excitation at 520 nm for EITC labeled platelets (i), and a peak at 520nm 
with excitation at 488 nm for FITC labeled platelets (ii).  In addition to the effects of the 
mere presence of PDI, the redox state of the deposited PDI was also investigated:  PDI 
was induced into a reduced, oxidized or isomerization state and then incubated with 
isolated platelets.  
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Figure 3-7  Verification of Mass Action deposition of redox modified or native 
state PDI onto the surface of isolated platelets.  PDI is labeled with FITC (green) 
and EITC (red); the uniform colour verifies deposition onto the entire surface of the 
platelet. 
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Figure 3-8  Fluorescence scan of i) EITC and ii) FITC labeled PDI, verifying the 
presence and fluorescence of the bound fluorophore 
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To verify the redox state of PDI, the Di-Eosin-GSSG assay (39) was utilized and the 
results are shown in figure 3-9.  Oxidized PDI will not cleave Di-Eosin-GSSG and 
therefore will not produce an appreciable increase in emission fluorescence at 540 nm, 
however in a fully reduced state PDI will display very fast cleavage of Di-Eosin-GSSG 
and produce a large spike in emission.  Hence, the ability to cleave GSSG is seen as a 
representation of oxidation state of the PDI molecule. 
 
3.2.1.1 Turbidity Assay 
To analyze the effect of excess PDI of various oxidation states on the aggregation 
rates of isolated platelets, turbidity experiments on the UV-VIS spectrometer were used 
to measure platelet aggregation.  Figure 3-10 shows the combined results from all redox 
modified PDI platelet aggregations over different days using a variety of blood donors.  
The results from the turbidity assay aggregations imply that excess surface PDI had no 
significant effect on the initial rates of platelet aggregation, nor did the oxidation state of 
excess surface PDI appear to have any effect.  From this general measure of platelet 
aggregation, PDI does not play a role in a rate limiting redox-dependent stage of the 
platelet aggregation pathway. 
 
  
Chapter 3: Results 
52 
 
 
Figure 3-9 Verification of redox state of PDI by the Di-Eosin-GSSG Assay (@540 
nm).  Reduced PDI cleaves Di-Eosin at the GSSG disulfide, causing an increase in 
fluorescence.  Oxidized PDI does not cleave the disulfides, thereby not producing an 
appreciable increase in fluorescence. Arrow indicates point at which PDI was 
added. 
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Figure 3-10 Initial rates of aggregation of isolated platelets incubated with PDI 
in various redox states; activated with 1 unit/mL thrombin, there is no significant 
difference in initial rates of aggregation between any of the treatments (n=31) 
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3.2.1.2 Aggregations Under Flow 
To confirm the results seen in the spectrophotometer, platelet adhesion studies were 
done using flow cell chambers and whole blood utilizing the various treatments of PDI.  
Isolated platelets were either incubated with native PDI, oxidized PDI, reduced PDI or 
left in an untreated state, then recombined with whole blood to perform the experiment.  
The result of incubating isolated platelets with excess PDI at a concentration of 1 μM is 
shown in Fig 3-11.  The results imply that incubating isolated platelets with excess PDI 
of native redox state had no influence on rates of adhesion of platelets to immobilized 
fibrinogen under flow conditions.  This implication was confirmed by the theoretical total 
aggregation curves from the same experiment, wherein platelets treated with excess PDI 
achieved lower total aggregation than untreated platelets (Fig 3-12). 
To verify the lack of effects on aggregation by redox induced PDI in the turbidity 
assays, the flow cell chamber experiment was utilized.  For this investigation, three 
approaches were attempted: first, only reduced glutathione (GSH) or oxidized glutathione 
(GSSG) at concentrations of 7.2 mM and 0.72 mM respectively were added to the whole 
blood preparation 2 minutes before beginning the flow; second, isolated platelets were 
pre-incubated with redox-induced PDI prior to mixing with whole blood preparation; 
lastly, a combination of the two approaches was utilized with both pre-incubated platelets 
and GSH/GSSG added directly into the whole blood preparation.  In all cases the results 
were inconclusive, with no statistical difference apparent between any of the treatment 
states (Fig 3-13).   
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Figure 3-11 Average kinetics of platelet adhesion to immobilized fibrinogen 
under flow.  Isolated platelets were pre-treated with or without excess PDI (1 μM).  
There is no significant difference between adhesion rates with or without excess PDI 
(n=3). 
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Figure 3-12  Total theoretical aggregation curves depicting platelet adhesion to 
immobilized fibrinogen under flow.  Theoretical curves are constructed based on the 
initial rates of adhesion for each trial (n=3). 
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Figure 3-13 Kinetics of platelet adhesion to immobilized fibrinogen under flow 
when treated with reduced or oxidized PDI, GSH or GSSG.  It was determined that 
there is no statistical difference between any of the treatment states. 
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In order to verify that the induced oxidation state in the flow cell chamber remains 
oxidized or reduced respectively throughout the entire experiment, plasma was isolated 
from the blood preparation and the concentration of free thiols was determined by 5,5'-
Dithio-bis (2-nitrobenzoic acid) (DTNB) Assay.  The DTNB assay confirmed that the 
induced redox state of the flow cell chamber preparation persists throughout the 
experiment (Fig 3-14).   
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Figure 3-14 Concentration of free thiols in post flow plasma as a percent of the 
pre-experiment thiol concentration.  The measured thiol concentration in plasma 
from the oxidized and reduced trials verifies that the redox state of the flow cell 
chamber environment remained oxidized and reduced respectively throughout the 
experiment.   
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3.2.2 Investigation into the role of excess b-b’ subunit of PDI on the platelet 
surface  
The b-b’ subunits of PDI were of interest as possibly being the main effectors of 
PDI’s documented augmentation of platelet aggregation.  Since these subunits are 
responsible for proper protein positioning in the PDI catalytic cleft, there was speculation 
that they could exert a chaperone activity on platelet surface integrins, holding the α2Bβ3 
integrin in such a way to enable intrinsic disulfide isomerase activity (14) or 
isomerization by glutathione (78).   
3.2.2.1 Turbidity Assay 
Isolated platelets were activated with 1 unit/mL thrombin and aggregation was 
measured in the UV-VIS Spectrophotometer as a function of the change in turbidity of 
the sample.  Initial rates of aggregation were compared between platelets treated with or 
without the b-b’ subunits of PDI.  Figure 3-15 shows the initial rates of aggregation 
between those platelets treated with b-b’ and those left untreated are not significantly 
different; as a result the b-b’ subunit of PDI does not appear to have its own chaperone 
function on the surface of platelets to potentiate aggregation. 
Chapter 3: Results 
61 
 
 
Figure 3-15 Initial rates of platelet aggregation following uncubation with 1 μM 
b-b'.  No statistical diffrence in the initial rates of aggregation was found between 
control and b-b' treated platelets (activated by thrombin (1 U/mL)) 
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3.2.2.3 Aggregations Under Flow 
To verify the effect of excess b-b’ on the platelet surface in a physiologically 
relevant setting, isolated labeled platelets were re-introduced into whole blood and 
pumped over flow cell chambers containing immobilized fibrinogen.  Following 
activation with calcium (4.6 mM), rates of adhesion are measured for all treatments (Fig 
3-16).  The turbidity assay results are confirmed by the more physiologically relevant 
flow cell chamber experiments and the chaperone-like role of the b-b’ subunit of PDI in 
platelet aggregation is unsupported.   
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Figure 3-16  Average kinetics of b-b' treated platelet adhesion to immobilized 
fibrinogen under flow.  There is no statistical difference found between treated and 
untreated platelets (n=5). 
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3.2.3 Hsp70 and its effects on platelet aggregation 
 
 
During routine ethanol wash of the platelet surface, Hsp70 was identified on SDS-
PAGE and Western blot (Fig 3-17); this was later confirmed by Suzanne Durocher in the 
Mutus Lab using gold nanoparticles to pull proteins off of the platelet surface 
(unpublished data). 
 
3.2.3.1 The Effect of Hsp70 on platelet aggregation and adhesion under flow 
conditions 
 
To test the potential role of cell surface Hsp70 in platelet aggregation, isolated 
platelets were incubated with Hsp70 prior to use in flow cell chamber experiments, much 
like the procedure used for PDI and the b-b’ subunit.  In addition, Hsp70 was added 
directly into the whole blood preparation prior to commencement of the flow cell 
chamber experiment.  In both cases the results were the same, with Hsp70 treated 
platelets having no significant difference in initial rates of adhesion from native platelets 
(Fig 3-18).  Figure 3-19 shows the images captured from various time points during the 
flow cell chamber experiment with excess Hsp70 on the surface of the platelet, 
confirming that there was no significant difference in platelet adhesion when excess 
Hsp70 was present on the platelet surface.  
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Figure 3-17  SDS-PAGE and western blot analysis of isolated platelet ethanol 
wash, identifying Hsp70 on the surface of the isolated platelet. 
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Figure 3-18 Kinetics of Hsp70 treated platelet adhesion to immobilized 
fibrinogen by activated platelets.  No difference was found between Hsp70 treated 
and untreated platelets. 
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Figure 3-19 Images from a flow cell chamber experiment depicting the 
progression of adhesion of Bodipy-FL labeled platelets to immobilized fibrinogen, 
when pre-treated with Hsp70 or left in their native state. 
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3.3 Thymosin Beta Four 
 
The effect of Tβ4 on platelet aggregation is a question that holds much promise and 
potential.  Tβ4 has been revealed to possess remarkable healing powers on the skin and 
eye (58, 63), however a hypothesis was developed implicating elevated levels of Tβ4 in 
diabetics and linking that to the elevated frequency of thrombotic events in persons with 
diabetes.  The turbidity assay and flow cell chamber experiment were implemented to test 
the effect of varying doses of Tβ4 on platelet aggregation and adhesion.   
 
3.3.1 Turbidity Assay 
 
Initially the effect of Tβ4 on platelet aggregation was assessed using turbidity assays 
in the UV-VIS Spectrophotometer.  At varying physiologically relevant doses of Tβ4 (1 
µg/mL to 100 µg/mL) the extent and initial rate of platelet aggregation was assessed as a 
function of decreased absorbance.  Figure 3-20 shows that Tβ4 influenced platelet 
aggregation at some doses, while having no effect at other doses.  At 1 µg/mL Tβ4 
appeared to slightly increase the initial rate of aggregation, however at 5 µg/mL and 10 
µg/mL there was a significant increase in initial rate of platelet aggregation over control.  
As the concentration of Tβ4 continued to increase, the positive effect on rate of 
aggregation diminished, and by 50 µg/mL the initial rates of aggregation were back to 
control levels.   
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Figure 3-20 Initial rates of aggregation of platelets treated with varying doses of 
TB4 in the turbidity assay (* = significant difference when P< 0.05; n=5) 
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3.3.2 The effect of Tβ4 on platelet adhesion under flow conditions 
 
To investigate the effects of Tβ4 on platelet aggregation in a more physiologically 
relevant experimental setting, Tβ4 was added at varying doses to the whole blood 
preparation prior to the onset of the flow cell chamber experiment.  In the flow cell 
chamber experiment, the same positive effect on platelet aggregation was seen in figure 
3-21 for Tβ4 doses of 1 µg/mL and 5 µg/mL; however, the 10 µg/mL dose did not appear 
to have the same effect as it did in the turbidity assay.  As observed previously, as the 
dose of Tβ4 increased above 10 µg/mL, the positive effect on platelet aggregation 
diminished back toward control levels. 
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Figure 3-21 Kinetics of platelet adhesion to immobilized fibrinogen under flow 
conditions at varying doses of TB4 (n=3) 
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3.3.3 Fibrinogen Binding of Tβ4 
 
Since the main platelet activation pathway targeted by the flow cell chamber 
experiments is the α2Bβ3 integrin pathway, which acts as a fibrinogen binding receptor 
(79), Tβ4 was tested to determine whether it was diminishing platelet aggregation at high 
doses by binding to fibrinogen, thereby preventing platelet adhesion.  Figure 3-22 shows 
the curve of FITC labeled Tβ4 binding to PDMS immobilized fibrinogen in a 96 well 
plate.  As the concentration of Tβ4 increases beyond 30 µg/mL, the binding of Tβ4 to 
fibrinogen begins to diminish as well; this points to Tβ4 not as an inhibitor of platelet 
aggregation at high concentrations, but rather as a switch acting to potentiate platelet 
aggregation rates at intermediate doses, while releasing from fibrinogen at high doses and 
allowing aggregation to occur at normal levels. 
The effect of Tβ4-fibrinogen binding on platelet aggregation was investigated in 
the spectrophotometer to confirm the hypothesis that intermediate doses of Tβ4 caused 
elevated initial rates of platelet aggregation.  Figure 3-23 shows the initial rates of 
aggregation as a percentage of control, and clearly shows that at the Tβ4 concentrations 
between 1 µg/mL and 10 µg/mL with fibrinogen present the rates of aggregation were 
lower than those without fibrinogen present; however at 30 µg/mL and 50 µg/mL the 
initial rates of aggregation converge.  Therefore it appeared that Tβ4 bound to free 
fibrinogen in the cuvette at intermediate doses, preventing the previously seen peak in 
initial rates of aggregation at 5 µg/mL.  When fibrinogen was immobilized in the flow 
cell chamber experiment, or absent in the cuvette, free Tβ4 was available for interaction 
with the platelet and augmentation of adhesion and aggregation.  
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Figure 3-22 Tβ4- fibrinogen binding curve.  Fibrinogen was immobilized on 
PDMS in a 96-well plate while EITC labeled Tβ4 was added at varying doses.  The 
resultant binding curve displays a relationship akin to first order kinetics, excepting 
the decrease in binding that occurs above [TB4] of 30 μg/mL (n=4). 
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Figure 3-23 Initial rates of aggregation of platelets in a turbidity assay shown as 
a percent of control.  Platelet aggregation was measured in the presence or absence 
or TB4 and fibrinogen. A peak at [TB4] 5 ug/mL correlates with the strong binding 
seen in the TB4-fibrinogen binding curve; in the presence of fibrinogen this peak in 
aggregation disappears (n=4).   
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Chapter 4 DISCUSSION 
4.1 Flow Cell Methodology Development 
 
In this study, the development of the flow cell chamber methodology was a focus in 
order to establish the method as a reliable and efficient tool for evaluating platelet 
adhesion under many conditions.  The eventual goal is to use the method diagnostically 
to assess platelet adhesion and aggregation in persons with bleeding disorders to 
determine the exact receptor, signaling molecule or pathway that is responsible for the 
problem.  Some difficulties encountered while working extensively with this method 
include bound platelet imaging problems; continuity of results between runs, between 
sessions and between blood sources; cracking and peeling of immobilized fibrinogen on 
PDMS causing unreliable adhesion counts; and clogging of the flow cell apparatus during 
runs.  The issue of bound platelet imaging is a difficult one to solve, mainly because the 
problem is that those platelets passing by the field of view at the moment the image is 
captured may not be stuck to the PDMS.  As a result the platelet adhesion count may be 
confounded by those platelets floating above the PDMS surface that are also captured in 
the image.  Although the flow rate is constant, this does not necessarily mean that the 
number of platelets passing by the field of view every second is the same—bubbles and 
currents that form in the chamber cause surges of platelet numbers at random times.  The 
ideal solution would be to find or make a fluorophore that becomes fluorescent after 
platelet adhesion to the protein matrix takes place; this is a very challenging concept, but 
perhaps enough knowledge about the receptor utilized to bind to the protein matrix, and 
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careful targeted labeling of that receptor, could allow this concept to be realized.  
Naturally if only bound platelets are emitting light, any issue with unbound platelets 
confounding fluorescent measurements would be eliminated.  Of the fluorescent labels 
assessed in this study, the most efficient and effective dye that does not display any 
inhibitory effects on platelet aggregation or fibrinogen-mediated platelet adhesion, is the 
Bodipy-FL fluorescent dye.  Although it is an exofacial thiol targeted dye, it appears that 
the thiols within the α2B β3, which are necessary for proper inside-out signaling to 
commence, are unaffected by this dye.   
The issue of continuity of results is a frustrating problem and although the trends 
are similar, the raw platelet adhesion numbers are always different from experiment to 
experiment, and sometimes can vary widely.  The same can be said for trials done within 
one experiment, with variations in the total adhesion numbers unexplainable by any of 
the methodology used in the experiment, as each trial is treated exactly the same as the 
one before and the one following, with controlled cell counts.  So although trends can be 
teased out, the error bars prevent significant statistical analysis of the data.  A potential 
solution to this problem remains evasive, as the only possible source of the problem 
would appear to be the methodology; however with each and every trial treated exactly 
the same, it becomes difficult to pinpoint the cause of this issue. 
The clogging of the flow cell apparatus is an indicator of both success and 
problems.  It indicates success because of the physiological relevance of the thrombosis 
occurring within the tubes, confirming that this method is very close to the process within 
the vessels of the body.  However, continuous clogging of the apparatus wastes blood and 
plasma stores, and it makes that chamber and that trial a waste as well.  Sometimes a 
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manipulation of a variable substantially increases platelet aggregability, but it leads to 
clogging of the apparatus before fibrinogen binding can be quantified.  Perhaps the small 
volume of blood that is continuously circulated causes thrombosis at such an elevated and 
perpetuated level upon addition of the calcium, that aggregation and thrombus formation 
occurs out of normal physiological levels.  Ideally a larger blood volume would be 
circulated, which requires access to very large volumes of fresh blood to allow for the 
number of trials that will be necessary to satisfy error.  Perhaps even direct circulation 
from a sedated animal to the chamber would provide the most physiologically relevant 
results. 
The issue of cracking and peeling of the immobilized fibrinogen dot was solvable, 
and the results are displayed in section 3.1.1.  Visually, it appeared that at concentrations 
of APTMES in ethanol higher than 5%, a dome-like APTMES dot formed.  With a dome 
shape, addition of any liquid substance at the apex of the dome—such as fibrinogen and 
BS3--resulted in gravitational movement of the liquid down the sides of the dome and 
deposition in a ring surrounding the dome.  Some fibrinogen became bound to BS3 on the 
surface of the APTMES dome, however the APTMES at the apex of the dome must not 
have covalently linked to the exposed functional groups on the surface of the PDMS due 
to simple distance restrictions.  Therefore, the lack of covalent bonds between PDMS and 
the apex of the APTMES dome resulted in cracking and peeling of the dome upon 
addition of sheer stress.  At APTMES concentrations of 5% or lower, the dome shape did 
not form—a spreading effect took place when the APTMES was applied to the surface of 
the PDMS.  The high ethanol content reduced the surface tension of the APTMES 
component, allowing the rapid spreading to occur and eliminating the production of a 
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‘dome; ethanol evaporated from the surface of the PDMS, leaving the PDMS-APTMES 
complex behind.  The downfall to this approach is that the area coated with fibrinogen is 
large: usually this area is larger than the field of view at 5x magnification, and as a result 
seeing platelet adhesion to the entire fibrinogen-coated area is not possible.   
 
4.2 Surface deposition of b-b’, PDI and Hsp70 and their effect on platelet 
aggregation 
 
In this study the effects of excess surface PDI, Hsp70 and the b-b’ subunit of PDI 
were investigated.  Excess surface protein was deposited on the platelet exofacial 
membrane through mass action deposition, and was verified by fluorescence microscopy.  
Experiments were performed on the treated platelets in the UV-VIS Spectrometer and on 
flow cell chamber apparatus, to determine if the excess surface protein had an effect on 
initial rates and extent of platelet aggregation.  There remains some question as to 
whether depositing excess protein on the surface of a cell should potentiate the 
aggregation response or not; it has been documented in the literature that PDI has an 
effect on platelet aggregation (47), and yet excess surface PDI did not cause significantly 
faster platelet aggregation.  So, perhaps more protein did not equate to a faster response, 
possibly due to the rate limiting step of the platelet reaction being upstream of the surface 
protein.  Given the increased levels of surface protein verified in figure 3-2, it follows 
that the excess protein was not internalized or cleaved; however, it is also possible that 
although the protein had been effectively deposited on the surface of the protein, that it 
was not being integrated into the network of effectors on the platelet surface that work 
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together and with synchronicity in order to realize the platelet reaction of aggregation and 
adhesion.  To combat these issues in the future it would be ideal to find ways of treating 
platelets to instigate upregulation of the proteins of interest, thereby making them 
completely native to the cell and integrated into the complex aggregation pathway.  
Furthermore, as many researchers have done in the past (47, 80-81), utilizing specific 
receptor antagonists to block or alter the proteins of interest would be another way to 
confirm the real-time effect of the protein of interest on platelet aggregation and 
adhesion.  While none of the effects of excess surface protein on platelet aggregation 
were statistically significant, the trends do reliably exist.  To be conclusive with these 
results smaller error bars would be required, and the ideas and suggestions outlined in 
section 4.1 would certainly help towards making that objective possible.  Additionally, 
due to the highly sensitive nature of platelets, very strict use of only one individual’s 
platelets taken at the same time of day, using the platelets the same length of time after 
being drawn, and doing enough trials at a time to be able to deduce statistically reliable 
results from one day’s experiments, would also help to reduce the error bars.   
 
4.3 Thymosin β4 
 
In this study, Tβ4 was investigated to determine if elevated levels caused increased 
rates of platelet aggregation and adhesion.  In the clinical setting patients with diabetes 
mellitus have been shown to suffer from clotting in the extremities causing lower body 
circulation problems, sometimes even resulting in foot or leg amputation.  Working with 
a hypothesis that elevated blood levels of Tβ4 could be contributing to the higher clotting 
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potential of diabetics, the presence of excess levels of Tβ4 was evaluated for effects on 
platelet aggregation in both the turbidity assays on the UV-VIS Spectrophotometer, and 
the whole blood flow cell chamber experiments.  In both cases, Tβ4 produced measurable 
results on platelet aggregation, with the most significant potentiating effects on platelet 
aggregation seen at 5 µg/mL; at much higher doses of Tβ4, the trend of potentiation 
disappeared.  To elucidate what could possibly be causing the trend to rise at intermediate 
levels of Tβ4 but diminish at higher levels of Tβ4, the relationship of Tβ4 with fibrinogen 
was analyzed.  Thymosin β4 was found to bind to PDMS-immobilized fibrinogen with a 
relationship akin to first-order kinetics (figure 3-22); as a result there was a direct 
relationship between the amount of Tβ4-fibrinogen binding and the concentration of Tβ4 
up to saturation at 30 µg/mL, with an estimated dissociation constant (Kd) of 25 nM.  
Beyond that saturation point, the extent of fibrinogen binding began to decrease, 
implying that beyond the saturation point Tβ4 was off-loading from fibrinogen.  This 
corroborates the trend seen in the turbidity and flow cell chamber data, where at 
intermediate concentrations of Tβ4 the effect on rate of platelet aggregation/adhesion was 
potentiating, however at higher concentrations of Tβ4 the effect on rate of platelet 
aggregation/adhesion was almost absent, resulting in rate levels very close to control.  To 
further corroborate this finding, platelet aggregations were performed in the UV-VIS 
Spectrophotometer with or without fibrinogen present, at varying doses of Tβ4.  A very 
intriguing trend was produced in this experiment: at lower doses of Tβ4, the peak in rate 
of platelet aggregation at 5 µg/mL disappeared with fibrinogen present, but the peak was 
present in the absence of fibrinogen.  Beyond Tβ4.concentrations of 10 µg/mL the rates of 
aggregation began to mirror each other, with rates in the presence of fibrinogen 
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approximately 5% lower than rates in the absence of fibrinogen.  Knowing that Tβ4 binds 
fibrinogen most effectively between the concentrations of 5 and 30 µg/mL and taking 
into account the very narrow Kd of 25 nM, it is probable that free fibrinogen and free 
Tβ4.were interacting in the cuvette above the [Tβ4] of 5 µg/mL, therefore sequestering it 
and preventing it from potentiating platelet aggregation.  However, at [Tβ4] of 10 µg/mL 
and above, the difference between the initial rates of platelet aggregation in the presence 
or absence of fibrinogen get sequentially smaller.  So, why does the binding strength in 
the cuvette appear to weaken at 10 µg/mL, while in the 96-well plate the binding strength 
appears to remain resilient until beyond 30µg/mL?  One consideration to make is that 
upon exposure to thrombin, platelets release Tβ4 in quantities of up to 6 fg/cell (61).  The 
concentration of Tβ4.indicated by the x-axis (figure 3-23) accounts for only the peptide 
added by experimental methods, not for any Tβ4.that may have been released by platelets.  
As a result, the concentration of Tβ4 may be higher than indicated on the x-axis when 
administered Tβ4 is taken into account in addition with Tβ4 released from platelets.  
Another possibility is that free fibrinogen binds Tβ4 with different dynamics than 
immobilized fibrinogen due to a difference in steric constraints placed on fibrinogen 
while it is immobilized.  Thus, fibrinogen may potentially become saturated at lower Tβ4 
concentrations when free in solution.  The well known actin binding domain LKKTETQ 
(82) does not have a clear binding sequence on fibrinogen, however in figure 4-1 are 
areas of consensus sequence between fibrinogen and Tβ4 where potential non-covalent 
interactions between fibrinogen and Tβ4 could occur. 
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Figure 4-1 Consensus sequences between fibrinogen and Tβ4 that may produce a 
binding site for Tβ4 on fibrinogen (images acquired from NCBI MMDB (83)) 
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However, Huff et al in 2002 identified covalent bond formation between Tβ4 and 
fibrinogen in the presence of tissue transglutaminase—which is co-released with Tβ4--
and suggest this as a mechanism to retain Tβ4 near the site of release (61).  Fixing Tβ4 
near the site of injury would theoretically make it available for participating in wound 
repair and healing, as the previously mentioned wound healing powers of Tβ4 are well 
documented.  It was further determined that the covalent bonds between fibrinogen and 
Tβ4 were isopeptide bonds formed between reactive Gln and Lys residues in both the α 
and γ chains of fibrinogen, with the most likely incorporation within the Aα392-610 
region of the fibrinogen αC domains (60).  Makogonenko et al., using concentrations 
higher than those utilized in this study, found that fibrinogen and Tβ4 do not form non-
covalent interactions in the absence of transglutaminase.  Interestingly this is not 
completely contradictory to the results outlined in this thesis, as at concentrations above 
30 µg/mL the binding relationship between fibrinogen and Tβ4 has been shown to trend 
back towards control levels; therefore it would be expected that at a concentration of 150 
µg/mL, as used in the Makogonenko paper, the interaction between fibrinogen and Tβ4 
would be relatively low.  When the Tβ4-fibrinogen binding curve is extrapolated to 
include a Tβ4 concentration of 150 μg/mL, it becomes clear that at 150 μg/mL 
concentration of Tβ4 the relative binding occurring between Tβ4 and fibrinogen is very 
close to the binding which occurs at very low (0.1 μg/mL) concentrations of Tβ4.  Hence, 
the Makogonenko finding, suggesting that fibrinogen and Tβ4 do not have noncovalent 
interactions, does not encompass the physiological range of Tβ4 concentrations utilized in 
this study; furthermore, the most important Tβ4 concentration range—around 5 μg/mL—
is not addressed at all.  Incorporating these results and the theories expressed in the 
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Makogonenko and Huff papers, the following hypothesis has been developed.  Upon 
initial platelet activation with thrombin Tβ4 is released, associating with the platelet 
surface and potentiating platelet aggregation.  At this point, since transglutaminase is co-
released with Tβ4, there is the potential for Tβ4 bonds with fibrinogen being formed, in a 
concentration-dependent manner according to Makogonenko et al.  Initially, the 
fibrinogen-Tβ4 binding would be relatively low as the concentration of Tβ4 would 
initially be low.  At this time, Tβ4 would be available to interact with the platelet surface, 
thereby potentiating platelet aggregation.  As more platelets become activated and the 
thrombus grows, the Tβ4 concentration would increase, with the proportion of the 
fibrinogen-Tβ4 bound complex subsequently growing.   Logically, the more clotting and 
platelet activation that occurs, the higher the Tβ4 concentration, and the more Tβ4 will be 
covalently bound to fibrinogen.  Thus, as the thrombotic event proceeds the body has 
essentially created not only a matrix which can keep Tβ4 at the site of injury for the 
purpose of wound repair, but a sink that in essence sequesters Tβ4 from the platelet 
surface, removing the potentiation signal.  By removing the potentiation signal, the body 
is preventing just one of the signals that would otherwise instigate an uncontrolled 
thrombotic event.  Clearly Tβ4 is not the only signaling molecule utilized for potentiation 
of the platelet aggregation reaction, so there are other components within the body that 
contribute to the down-regulation of the aggregation response after the bleeding at the 
site of injury has been stopped.  However, it appears that the sequestration of Tβ4 by 
tissue transglutaminase and fibrinogen may be one of those processes participating in this 
cascade.  For diabetic patients, slightly elevated levels of Tβ4 in platelets or in the blood 
could contribute to the increased propensity for thromboses, while high doses of Tβ4 
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could represent a potential therapy for treatment of the thrombotic side effects of diabetes 
and other illnesses such as cardiovascular disease and atherosclerosis. 
4.4 Future Directions 
 
For future directions of this study, the most significant and important ones are as 
follows: further development of the flow cell chamber experimental method, and further 
investigation into Tβ4 as a factor in thrombotic symptoms of diabetes, and possibly as a 
thrombotic inhibitor at high concentrations.  To expand the experimental method of flow 
cell chamber experiments, the problems previously discussed in this study must be solved 
including the imaging of bound platelets, continuity of results from trial to trial and 
experiment to experiment, as well as implementing a technique to prevent the system 
from clogging and wasting valuable materials.  As previously mentioned the most ideal 
solution to the problem of imaging bound platelets—while avoiding unbound platelets 
flowing above the PDMS surface—is developing a labeling technique that only allows 
platelets to become fluorescent once they have bound to fibrinogen on the PDMS surface.  
To prevent the system from clogging, it might be effective to use a larger blood source to 
prevent blood and the platelets therein from continuously being exposed to the stresses 
within the tube system, as in the current experimental set up.  With a larger blood volume 
to pull from, platelets and red blood cells returning to the blood pool would theoretically 
have a longer wait time before being sucked back into the tube system, thus 
administering less stress per cell. 
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 Further investigation into Tβ4 as a potential culprit in diabetic thromboses would 
require analysis of diabetic patients and their Tβ4 levels, along with comparisons between 
the effects of Tβ4 administration effects on diabetic platelets and compared to control 
platelets.  Extending the study of Tβ4 as an anti-thrombotic compound at high 
concentrations of administration would require studying the concept in animal models, 
inducing thrombotic events and measuring their severity at varying doses of Tβ4.  
Furthermore, to confirm the location of the binding pocket on fibrinogen for Tβ4, 
mutational studies would need to be conducted altering amino acids within the proposed 
binding pocket and measuring the effect of those mutations on Tβ4 binding.  Once the 
binding pocket for Tβ4 could be verified, further research would be needed to elucidate 
the pathway including Tβ4 as an effector in platelet aggregation, and how fibrinogen 
plays a role in this pathway.   
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